ETFIQData as of Nov 18, 2026. · etfiq.com/funds/ihe

IHE Fact Sheet: iShares U.S. Pharmaceuticals ETF

Share
$107.05
close, Nov 18, 2026

Over the year to Nov 18, 2026, IHE returned +32.9% in total and charged 0.37% a year.

1-year total return
+32.9%
to Nov 18, 2026
Expense ratio
0.37%
a year
Net assets
$1.7bn
on Nov 18, 2026
Net flow, last 5 trading days
+$22.1m
daily basis to Nov 17, 2026

Growth of $10,000, 1 year

IHE $13,288 +32.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month+6.4%
3 months−0.8%
Year to date+27.3%
1 year+32.9%
3 years+94.3%
5 years+81.9%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
ELI LILLY & COMPANY26.70%
JOHNSON & JOHNSON22.13%
VIATRIS4.88%
ZOETIS INC CLASS A4.83%
ROYALTY PHARMA PLC CLASS A4.81%
PFIZER4.35%
MERCK & CO INC4.12%
BRISTOL MYERS SQUIBB4.04%
JAZZ PHARMACEUTICALS PLC3.24%
ELANCO ANIMAL HEALTH2.68%

IHE top ten by weight, 81.8% of the fund, of its 52 equity positions, from the holdings published by its issuer for Nov 17, 2026.

Facts

Equity fund · Tracks the Dow Jones U.S. Select Pharmaceuticals Index · First traded May 5, 2006 · Benchmark Its own holdings, as of Nov 17, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, IHE Fact Sheet: iShares U.S. Pharmaceuticals ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/ihe/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/ihe.